Equities

Infinium Pharmachem Ltd

INFINIUM:NSI

Infinium Pharmachem Ltd

Actions
  • Price (INR)328.80
  • Today's Change0.80 / 0.24%
  • Shares traded6.00k
  • 1 Year change+33.66%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 09:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Infinium Pharmachem Limited is an India-based company. The Company is engaged in the development, manufacture, and export of a spectrum of the Iodine Derivatives that are used in pharmaceutical, chemical, biotech and allied industries across the globe. The Company's portfolio includes approximately 200+ Iodine Derivatives and seven Active Pharmaceutical Ingredients (APIs). It manufactures and supplies a range of Iodine based APIs, but on Order to Made basis only. It offers bulk actives, intermediates and services for custom synthesis. It also provides contract Research and manufacturing Services to the pharmaceutical and biotech companies for their diverse requirements of Iodine based APIs and intermediates to reduce their research time and project cost. It manufactures iodine derivatives for various industries, including pharmaceutical, chemical, nutraceutical, cosmetics, agrochemical, electronics, Nylon production, and other industries for their range of industrial applications.

  • Revenue in INR (TTM)1.36bn
  • Net income in INR113.02m
  • Incorporated2003
  • Employees118.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Poddar Pigments Ltd3.79bn286.10m3.85bn346.0013.471.0210.651.0226.9626.96357.07357.190.92563.676.0410,951,430.006.998.217.759.0131.3126.287.557.543.0795.480.008.348.320.65895.4111.754.425.92
Purv Flexipack Ltd2.54bn59.94m4.06bn30.0048.443.1836.011.603.993.99141.2360.88------84,725,700.00--------10.54--2.95--1.410.61620.5032---23.71---35.75------
Asahi Songwon Colors Ltd5.04bn101.49m4.32bn126.0042.571.7717.740.85758.618.61427.90207.010.8864.054.4040,000,110.001.143.131.934.9731.7126.661.283.480.81341.570.419710.32-15.527.74272.091.8562.20-30.12
Mangalam Organics Ltd4.72bn72.93m4.40bn307.0060.531.5515.890.93158.488.48549.21332.050.85291.586.8815,375,070.001.308.472.3412.1842.6231.881.527.470.44031.470.4842--0.20173.05116.19-42.918.11--
Infinium Pharmachem Ltd1.36bn113.02m4.58bn118.0040.497.7832.293.378.128.1297.4742.241.744.417.5611,494,850.0014.74--23.19--23.99--8.48--2.187.240.1573--18.75--19.10------
Valiant Laboratories Ltd1.50bn-44.58m4.83bn--------3.23-1.04-1.0438.88------------------3.07---2.98-----149.46-----45.48---98.90------
Diamines And Chemicals Ltd884.34m57.64m5.06bn151.0087.173.1153.975.735.945.9489.15166.440.51561.576.425,856,557.003.4821.923.7923.6847.0661.086.7628.953.8535.140.026514.38-5.9117.07-63.083.33-1.79-12.94
Nova Agritech Ltd2.74bn289.78m5.30bn--15.562.6017.221.933.783.7833.7122.68----------------33.92--10.58--2.225.460.216--19.91--38.16------
Data as of Nov 14 2024. Currency figures normalised to Infinium Pharmachem Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.